Grupo mixto en cáncer
Coordinador/a del grupo
-
Miguel Unda Urzaiz
Coordinador de grupo
jesusmiguel.undaurzaiz@osakidetza.eus -
Arkaitz Carracedo Pérez
Coordinador de grupo
arkaitz.carracedoperez@osakidetza.eus
CV resumen
Publicaciones del grupo
Larrinaga G, Valdivia A, Arrieta Aguirre I, Solano Iturri JD, Ugalde Olano A, Loizaga Iriarte A, et al. The Expression of Alamandine Receptor MrgD in Clear Cell Renal Cell Carcinoma Is Associated with a Worse Prognosis and Unfavorable Response to Antiangiogenic Therapy. Int J Mol Sci. 2024; 25(3). DOI:10.3390/ijms25031499.
Unda M, Cozar Olmo JM, Alvarez Osorio JL. Why is it necessary to produce a BCG strain in Spain?. Actas Urol Esp (Engl Ed). 2024; 48(7): 487-489. DOI:10.1016/j.acuroe.2024.04.003.
Gil Redondo R, Conde R, Bruzzone C, Seco ML, Bizkarguenaga M, González Valle B, et al. MetSCORE: a molecular metric to evaluate the risk of metabolic syndrome based on serum NMR metabolomics. Cardiovasc Diabetol. 2024; 23(1). DOI:10.1186/s12933-024-02363-3.
Rodriguez Faba O, Fernandez Gomez JM, Guerrero Ramos F, Alvarez Maestro M, Ledo Cepero MJ, Unda Urzaiz M, et al. Consensus document on the implications of standardization of BCG supply in the management of patients with non-muscle-invasive bladder cancer. Actas Urol Esp (Engl Ed). 2024; 48(10): 718-731. DOI:10.1016/j.acuroe.2024.09.005.
Borque Fernando A, Perez Fentes DA, Rodrigo Aliaga M, Puente Vazquez J, Gomez Iturriaga A, Unda M, et al. Optimizing triple therapy in patients with metastatic hormone-sensitive prostate cancer. Actas Urol Esp (Engl Ed). 2024. DOI:10.1016/j.acuroe.2024.10.005.
Álvarez Ossorio JL, Rodrigo Aliaga M, Rodríguez Antolin A, Unda Urzaiz M, Calleja MÁ, de la Cruz Ruiz M, et al. Hormone sensitive protocol for metastatic prostate cancer, an update. Actas Urol Esp (Engl Ed). 2023; 47(4): 244-249. DOI: 10.1016/j.acuroe.2022.10.002.
Loizaga Iriarte A, Lacasa Viscasillas I, Rey Gonzalez S, Santos Martin A, Gonzalo Aparicio D, Ugalde Olano A, et al. Identifying prognostic parameters related to surgical technique in patients treated by robotic radical prostatectomy. Actas Urol Esp (Engl Ed). 2023; 47(1): 47-55. DOI: 10.1016/j.acuroe.2022.07.001.
Angulo JC, Álvarez-Ossorio JL, Domínguez-Escrig JL, Moyano JL, Sousa A, Fernández JM, et al. Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial. Eur Urol Oncol. 2023; 6(1): 58-66. DOI: 10.1016/j.euo.2022.10.008.
Martín-Saiz L, Abad-García B, Solano-Iturri JD, Mosteiro L, Martín-Allende J, Rueda Y, et al. Using the Synergy between HPLC-MS and MALDI-MS Imaging to Explore the Lipidomics of Clear Cell Renal Cell Carcinoma. Anal Chem. 2023; 95(4): 2285-2293. DOI: 10.1021/acs.analchem.2c03953.
Borque-Fernando A, Calleja-Hernández MA, Cózar-Olmo JM, Gómez-Iturriaga A, Pérez-Fentes DA, Puente-Vázquez J, et al. A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer. Actas Urol Esp (Engl Ed). 2023; 47(2): 111-126. DOI: 10.1016/j.acuroe.2022.12.004.
Borque-Fernando A, Calleja-Hernández MA, Cózar-Olmo JM, Gómez-Iturriaga A, Pérez-Fentes DA, Puente-Vázquez J, et al. Abiraterone in low-volume metastatic hormone-sensitive prostate cancer. Authors' reply. Actas Urol Esp (Engl Ed). 2023; 47(6): 392-393. DOI: 10.1016/j.acuroe.2023.04.014.
García-Vílchez R, Añazco-Guenkova AM, Dietmann S, López J, Morón-Calvente V, D'Ambrosi S, et al. METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer. Mol Cancer. 2023; 22(1): 119. DOI: 10.1186/s12943-023-01809-8.
Carracedo A. Metabolism in the tumor cell and beyond. Mol Oncol. 2023; 17(6): 921-924. DOI: 10.1002/1878-0261.13467.
Plou J, Valera PS, García I, Vila-Liarte D, Renero-Lecuna C, Ruiz-Cabello J, Carracedo A, Liz-Marzán LM. Machine Learning-Assisted High-Throughput SERS Classification of Cell Secretomes. Small. 2023 12:e2207658. DOI: 10.1002/smll.202207658.
Santasusagna S, Zhu S, Jawalagatti V, Carceles-Cordon M, Ertel A, Garcia-Longarte S, et al. Master Transcription Factor Reprogramming Unleashes Selective Translation Promoting Castration Resistance and Immune Evasion in Lethal Prostate Cancer. Cancer Discov. 2023; 13(12): 2584-2609. DOI: 10.1158/2159-8290.CD-23-0306..
Tesis del grupo
Autor/a: Mikel Pujana Vaquerizo. Título: Molecular and biological consequences of targeting polyamine metabolism in prostate cancer. Directores/as: Arkaitz Carracedo Pérez, Amaia Zabala Letona. URL: http://hdl.handle.net/10810/61339.
Autor/a: Cristina Viera Bardón. Título: Metabolic control of prostate cancer aggressiveness by the tumor stroma. Directores/as: Arkaitz Carracedo Pérez, Janire Astobiza Pérez. URL: http://hdl.handle.net/10810/61590.
